Dupilumab Improved Esophageal Function in REMODEL Trial
The phase 4 study found that dupilumab increased esophageal distensibility in adults with eosinophilic esophagitis.
Updated on Oct. 12, 2026 in Asthma
Live Poll
Do you trust pharmaceutical treatments to replace the need for traditional physical medical procedures?
Results from the phase 4 REMODEL trial indicate that weekly 300 mg doses of dupilumab significantly improved esophageal distensibility in adults with eosinophilic esophagitis. Participants treated with the drug showed a mean distensibility plateau increase of 1.28 mm over 24 weeks compared to a 0.01 mm decrease in the placebo group.
Why it matters
This trial was designed to evaluate whether pharmacological intervention can reverse structural esophageal changes caused by eosinophilic esophagitis without the need for physical dilation. The findings suggest a potential non-invasive path for managing esophageal remodeling in patients with the chronic condition.
The REMODEL trial enrolled 69 adult participants, with 44% having undergone esophageal dilation prior to study entry. Treatment with dupilumab reduced the total EoE Endoscopic Reference Score by a difference of -4.96 compared to the placebo arm.
The players
University of North Carolina
This public research university in Chapel Hill is home to the lead researchers who conducted the REMODEL trial.
The details
Researchers utilized an endoluminal functional lumen imaging probe to measure esophageal distensibility during the study period. By prohibiting clinical dilation, investigators were able to isolate the biological effects of dupilumab on tissue structure.
Timeline
The primary trial period lasted for 24 weeks.
Trial results were presented at an ACG meeting in Nashville from October 9-14, 2026.
A 2-year open-label extension study will further assess patient outcomes.
The Big Picture
This study marks a significant step in the clinical evaluation of the REMODEL trial. The findings extend existing knowledge regarding the use of biologic therapies to treat structural changes in the digestive tract.
Patients with eosinophilic esophagitis may eventually have access to therapeutic options that address structural remodeling without requiring mechanical dilation. This development could offer a new, non-invasive approach to managing long-term symptoms and esophageal health.
The takeaway
The REMODEL trial successfully demonstrated that biological therapy could improve physical esophageal function in adults. These results provide a foundation for future studies focusing on long-term structural maintenance without invasive procedures.
What happens next
A 2-year open-label extension study is planned to assess whether esophageal caliber continues to improve. Additional data regarding epithelial barrier function are expected at an upcoming European gastroenterology meeting.
Further reading
For additional context on chronic respiratory and inflammatory conditions, visit the Asthma section.
More information
Review the full study protocols and participant data via the REMODEL trial clinical study information.
Live Poll
Do you trust pharmaceutical treatments to replace the need for traditional physical medical procedures?
